Stallergenes gains U.S. FDA approval for Oralair allergy drug

April 1, 2014 11:31 PM

17 0

April 1 (Reuters) - France's Stallergenes said on Tuesday it received the U.S. Food and Drug Administration's green light to sell its immunotherapy pill Oralair for treating grass allergies.

The drug is a fast-dissolving tablet to be placed under the tongue that contains extracts from five grass pollens: sweet vernal, orchard, perennial rye, timothy and Kentucky bluegrass. It harnesses the immune system to alleviate allergies and is an alternative to current injectable treatments.

Read more

To category page